BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

Cancer Immunology Research
Sherille D BradleyGregory Lizée

Abstract

Oncogene activation in tumor cells induces broad and complex cellular changes that contribute significantly to disease initiation and progression. In melanoma, oncogenic BRAF(V600E) has been shown to drive the transcription of a specific gene signature that can promote multiple mechanisms of immune suppression within the tumor microenvironment. We show here that BRAF(V600E) also induces rapid internalization of MHC class I (MHC-I) from the melanoma cell surface and its intracellular sequestration within endolysosomal compartments. Importantly, MAPK inhibitor treatment quickly restored MHC-I surface expression in tumor cells, thereby enhancing melanoma antigen-specific T-cell recognition and effector function. MAPK pathway-driven relocalization of HLA-A*0201 required a highly conserved cytoplasmic serine phosphorylation site previously implicated in rapid MHC-I internalization and recycling by activated immune cells. Collectively, these data suggest that oncogenic activation of BRAF allows tumor cells to co-opt an evolutionarily conserved MHC-I trafficking pathway as a strategy to facilitate immune evasion. This link between MAPK pathway activation and the MHC-I cytoplasmic tail has direct implications for immunologic recognitio...Continue Reading

References

Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·M A Vega, J L Strominger
Jan 1, 1984·The Journal of Experimental Medicine·D B Tse, B Pernis
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·M GromméJ Neefjes
Oct 31, 2002·Nature Immunology·Hung T Khong, Nicholas P Restifo
Oct 31, 2002·Nature Immunology·Jonathan W Yewdell, Ann B Hill
Mar 5, 2005·Trends in Immunology·Gregory LizéeWilfred A Jefferies
Jun 28, 2006·The Journal of Experimental Medicine·Hidetoshi SumimotoYutaka Kawakami
Oct 24, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Laura A JohnsonSteven A Rosenberg
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Dec 14, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James S WilmottRichard A Scolyer
Jul 14, 2012·Nature Reviews. Immunology·Olivier P JoffreSebastian Amigorena
Aug 2, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jahan S KhaliliGregory Lizée
Sep 6, 2012·Proceedings of the National Academy of Sciences of the United States of America·Xiuju LuRajat Varma
Dec 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chengwen LiuPatrick Hwu
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dennie T FrederickJennifer A Wargo
Mar 5, 2013·The Journal of Clinical Investigation·Deborah A KnightMark J Smyth
Mar 14, 2013·Oncoimmunology·Bishu SapkotaBrian P Pollack
Mar 26, 2013·Oncoimmunology·Jahan S KhaliliGregory Lizée
Nov 19, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kousaku MimuraKoji Kono

❮ Previous
Next ❯

Citations

Apr 9, 2016·Oncoimmunology·Sherille D BradleyGregory Lizée
Dec 20, 2016·Laboratory Investigation; a Journal of Technical Methods and Pathology·Mario MandalàDaniela Massi
Oct 25, 2016·The Lancet. Diabetes & Endocrinology·Jena D FrenchMabel Ryder
Jan 20, 2017·Nature·Daniel S Chen, Ira Mellman
Jul 12, 2018·Current Opinion in Oncology·Giovanni FucàMassimo Di Nicola
Nov 15, 2017·Journal of Clinical Pharmacology·Anna E KershBrian P Pollack
Apr 13, 2019·Expert Opinion on Drug Safety·Kristy Kummerow BromanJonathan S Zager
Jan 7, 2020·Expert Review of Anticancer Therapy·Dimitrios C ZiogasHelen Gogas
Jul 21, 2016·BMC Immunology·Karla K FrietzeLisa M Boulanger
Feb 1, 2020·Expert Review of Anticancer Therapy·Sheida Naderi-Azad, Ryan Sullivan
Feb 15, 2020·Cells·Matilde MontiWilliam Vermi
Mar 21, 2020·Expert Review of Anticancer Therapy·Claudia TrojanielloPaolo A Ascierto
Jul 11, 2020·Cancers·Ilaria ProiettiConcetta Potenza
Jul 16, 2020·Expert Review of Anticancer Therapy·Erin McClureJonathan S Zager
Nov 9, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Randy R Brutkiewicz
Apr 26, 2016·The Cancer Journal·Peter A PrietoJennifer A Wargo
May 18, 2019·American Society of Clinical Oncology Educational Book·Pradnya Dinkar PatilDavid H Johnson
May 17, 2017·Oncoimmunology·Giulia ChiaruttiniSophia N Karagiannis
Aug 28, 2020·Frontiers in Cell and Developmental Biology·Xue-Jiao HanXia-Wei Wei
Aug 21, 2020·Nature Reviews. Immunology·Devin DershJonathan W Yewdell
May 26, 2017·Cancer·Robert A Szczepaniak SloaneJennifer A Wargo
Jul 16, 2015·Pigment Cell & Melanoma Research·Ha Linh VuAndrew E Aplin
Mar 28, 2020·Molecular Carcinogenesis·Hang RuanJian Yu
Jul 23, 2020·Frontiers in Chemistry·Shuang YueShuang Wei
Dec 5, 2020·Cancer Immunology, Immunotherapy : CII·Lukas PeifferJürgen C Becker
Feb 18, 2016·Cancer Immunology Research·Stephanie ZdanovSamir N Khleif

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.